Axiom Real-Time Metrics Attending J.P. Morgan Healthcare and Biotech Showcase Conferences
08 janv. 2023 22h06 HE
|
Axiom Real-Time Metrics Inc
TORONTO, Jan. 08, 2023 (GLOBE NEWSWIRE) -- Axiom Real-Time Metrics ("Axiom"), a premier provider of unified eClinical solutions and services focused on small-to-medium life science organizations,...
FDA Approves IND Submission Allowing ABVC BioPharma to Proceed With Clinical Study of ABV-1519 for Treatment of Non-Small Cell Lung Cancer
05 janv. 2023 08h30 HE
|
ABVC BioPharma, Inc.
FREMONT, CA, Jan. 05, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
Purple Biotech and Mor Research Applications Announce Research Collaboration to Identify Promising Investigational Oncology Treatments
03 janv. 2023 07h00 HE
|
Purple Biotech Ltd.
REHOVOT, Israel, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and...
Clinical ink Selected for Global Late Phase Parkinson’s Disease Programs
15 déc. 2022 08h42 HE
|
Clinical Ink
Horsham, PA, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Clinical ink, a global life science technology company, has partnered with a leading biopharmaceutical organization focused on Parkinson’s Disease...
InflaRx Initiates First-in-Human Study with Small Molecule C5aR Inhibitor INF904
09 nov. 2022 07h40 HE
|
InflaRx N.V.
Randomized, double-blind, placebo-controlled Phase I trial of orally administered complement inhibitor INF904 initiatedStudy designed as single ascending dose to determine safety, tolerability and...
SciSparc Announced Positive Interim Results Meeting Primary Endpoints at Phase IIa Study in Alzheimer’s Disease Patients with Agitation
07 nov. 2022 08h45 HE
|
SciSparc Ltd
Meets primary endpoints- SCI-110 administration was found to be safe at all tested dosesSCI-110 treatment was also found to reduce agitation - 75% of patients did not need to use additional medication...
CROSSJECT - CLINICAL DEMONSTRATION OF ZENEO® EFFICIENCY FOR INTRAMUSCULAR INJECTION OF MIDAZOLAM
02 nov. 2022 03h00 HE
|
CROSSJECT
Press release CLINICAL DEMONSTRATION OF ZENEO® EFFICIENCY FOR INTRAMUSCULAR INJECTION OF MIDAZOLAM • Primary endpoints met and results in line with expectations• No impact of clothing on the...
CROSSJECT - Validation clinique de l’efficacité de ZENEO® pour l’injection intramusculaire de midazolam
02 nov. 2022 03h00 HE
|
CROSSJECT
Communiqué de presse Validation clinique de l’efficacité de ZENEO® pour l’injection intramusculaire de midazolam • Paramètres primaires atteints et résultats conformes aux attentes Pas d’impact du...
IMAC Holdings, Inc. Announces Completion of Third Cohort of its Phase 1 Clinical Study of Umbilical Cord-Derived Mesenchymal Stem Cells for the Treatment of Bradykinesia Due to Parkinson’s Disease
09 sept. 2022 09h22 HE
|
IMAC Holdings, Inc.
BRENTWOOD, Tenn., Sept. 09, 2022 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: BACK) (“IMAC” or “the Company”), today announces it has completed the third cohort of its Phase 1 clinical trial for...
Florida Cancer Specialists & Research Institute Physicians Present Cancer Care Advancements at Global Oncology Gathering
08 sept. 2022 12h30 HE
|
Florida Cancer Specialists & Research Institute
Fort Myers, Fla., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Research conducted by Florida Cancer Specialists & Research Institute, LLC (FCS) is among the latest cutting-edge developments and findings...